Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aspirin prevention study in BRCA1/2 carriers undergoing risk-reducing ovarian surgery
ACTRN12619000520134Phase 2Terminated
- Sponsor
- University of Sydney
- Start
- Jun 2020
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in ovarian cancer comparing Aspirin with Placebo (2 arms). Primary endpoint: Frequency of pre-malignant and malignant tubal/ovarian lesions at risk-reducing surgery. Started Jun 2020; status: terminated.
02
Drugs
aspirin
03
Conditions
ovarian cancer
Beyond the preview
Go deeper on ACTRN12619000520134.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12619000520134.